Outlook Therapeutics IncNASDAQ:OTLK
- LAST PRICE8.5600
- TODAY'S CHANGE (%)0.2200 (2.6379%)
- Bid / Lots8.0000/ 1
- Ask / Lots9.2500/ 2
- Open / Previous Close8.5300 / 8.3400
- Day Range
- 52 Week Range
- Volume303,609
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OTLK |
|---|---|---|
| 09:32 ET | 472 | 8.53 |
| 09:36 ET | 695 | 8.65 |
| 09:45 ET | 3259 | 8.56 |
| 09:48 ET | 13850 | 8.66 |
| 09:50 ET | 17175 | 8.62 |
| 09:52 ET | 1518 | 8.665 |
| 09:54 ET | 830 | 8.69 |
| 09:56 ET | 500 | 8.66 |
| 09:57 ET | 800 | 8.65 |
| 09:59 ET | 300 | 8.6799 |
| 10:06 ET | 939 | 8.6 |
| 10:14 ET | 1470 | 8.46 |
| 10:15 ET | 6134 | 8.5 |
| 10:17 ET | 700 | 8.49 |
| 10:19 ET | 200 | 8.485 |
| 10:21 ET | 394 | 8.47 |
| 10:26 ET | 2877 | 8.5 |
| 10:30 ET | 1000 | 8.525 |
| 10:32 ET | 4975 | 8.45 |
| 10:33 ET | 3100 | 8.41 |
| 10:35 ET | 100 | 8.445 |
| 10:42 ET | 100 | 8.49 |
| 10:46 ET | 100 | 8.47 |
| 10:48 ET | 100 | 8.5 |
| 10:50 ET | 2400 | 8.5 |
| 10:51 ET | 2200 | 8.465 |
| 10:55 ET | 500 | 8.435 |
| 10:57 ET | 1200 | 8.41 |
| 11:00 ET | 100 | 8.47 |
| 11:04 ET | 100 | 8.46 |
| 11:06 ET | 800 | 8.49 |
| 11:08 ET | 2009 | 8.42 |
| 11:09 ET | 100 | 8.42 |
| 11:15 ET | 100 | 8.445 |
| 11:22 ET | 800 | 8.47 |
| 11:24 ET | 1000 | 8.4511 |
| 11:27 ET | 300 | 8.465 |
| 11:29 ET | 4437 | 8.49 |
| 11:36 ET | 1900 | 8.455 |
| 11:40 ET | 400 | 8.48 |
| 11:42 ET | 100 | 8.48 |
| 11:44 ET | 55513 | 8.48 |
| 11:45 ET | 3199 | 8.4405 |
| 11:49 ET | 9124 | 8.44 |
| 11:51 ET | 1000 | 8.465 |
| 12:00 ET | 200 | 8.48 |
| 12:02 ET | 2800 | 8.49 |
| 12:03 ET | 300 | 8.52 |
| 12:05 ET | 1707 | 8.52 |
| 12:07 ET | 400 | 8.5004 |
| 12:14 ET | 3984 | 8.49 |
| 12:16 ET | 500 | 8.52 |
| 12:18 ET | 1506 | 8.525 |
| 12:20 ET | 507 | 8.51 |
| 12:32 ET | 2511 | 8.51 |
| 12:36 ET | 1100 | 8.5 |
| 12:39 ET | 1708 | 8.48 |
| 12:41 ET | 3884 | 8.4941 |
| 12:43 ET | 953 | 8.48 |
| 01:03 ET | 2200 | 8.45 |
| 01:06 ET | 800 | 8.4602 |
| 01:08 ET | 100 | 8.465 |
| 01:12 ET | 300 | 8.465 |
| 01:14 ET | 800 | 8.46 |
| 01:17 ET | 5920 | 8.41 |
| 01:19 ET | 300 | 8.43 |
| 01:21 ET | 200 | 8.43 |
| 01:26 ET | 4402 | 8.43 |
| 01:28 ET | 200 | 8.43 |
| 01:30 ET | 100 | 8.43 |
| 01:35 ET | 7101 | 8.37 |
| 01:37 ET | 2200 | 8.34 |
| 01:39 ET | 400 | 8.35 |
| 01:42 ET | 100 | 8.36 |
| 01:46 ET | 550 | 8.365 |
| 01:48 ET | 600 | 8.39 |
| 01:50 ET | 405 | 8.435 |
| 01:53 ET | 300 | 8.44 |
| 01:55 ET | 300 | 8.4402 |
| 02:02 ET | 1200 | 8.47 |
| 02:04 ET | 7736 | 8.5 |
| 02:06 ET | 400 | 8.49 |
| 02:08 ET | 849 | 8.485 |
| 02:09 ET | 3593 | 8.5 |
| 02:11 ET | 400 | 8.5 |
| 02:13 ET | 100 | 8.51 |
| 02:15 ET | 2000 | 8.5004 |
| 02:18 ET | 4265 | 8.495 |
| 02:20 ET | 200 | 8.48 |
| 02:22 ET | 200 | 8.46 |
| 02:24 ET | 100 | 8.455 |
| 02:26 ET | 100 | 8.465 |
| 02:27 ET | 100 | 8.465 |
| 02:29 ET | 100 | 8.45 |
| 02:31 ET | 100 | 8.465 |
| 02:33 ET | 900 | 8.48 |
| 02:38 ET | 1300 | 8.495 |
| 02:40 ET | 100 | 8.495 |
| 02:42 ET | 1900 | 8.48 |
| 02:44 ET | 1035 | 8.44 |
| 02:45 ET | 200 | 8.45 |
| 02:47 ET | 900 | 8.445 |
| 02:49 ET | 100 | 8.445 |
| 02:51 ET | 900 | 8.5 |
| 02:54 ET | 100 | 8.495 |
| 02:56 ET | 400 | 8.495 |
| 03:03 ET | 100 | 8.48 |
| 03:05 ET | 300 | 8.495 |
| 03:07 ET | 1300 | 8.48 |
| 03:12 ET | 354 | 8.495 |
| 03:14 ET | 200 | 8.495 |
| 03:18 ET | 1700 | 8.52 |
| 03:21 ET | 100 | 8.515 |
| 03:25 ET | 100 | 8.51 |
| 03:27 ET | 1498 | 8.525 |
| 03:30 ET | 3400 | 8.495 |
| 03:36 ET | 2533 | 8.47 |
| 03:38 ET | 453 | 8.48 |
| 03:39 ET | 1810 | 8.51 |
| 03:43 ET | 100 | 8.51 |
| 03:50 ET | 100 | 8.52 |
| 03:52 ET | 1289 | 8.515 |
| 03:54 ET | 3857 | 8.5 |
| 03:56 ET | 1599 | 8.51 |
| 03:57 ET | 2975 | 8.53 |
| 03:59 ET | 14440 | 8.56 |
Jul 8, 2024
Outlook Therapeutics(R) Announces UK MHRA Marketing Authorization of LYTENAVA(TM) (bevacizumab gamma) for the Treatment of Wet AMD, from 8:35AM ET on Monday Jul 08, 2024 by Dow Jones
8:35AM ET on Monday Jul 08, 2024 by Dow JonesOutlook Therapeutics(R) Announces UK MHRA Marketing Authorization of LYTENAVA(TM) (bevacizumab gamma) for the Treatment of Wet AMD, from 8:35AM ET on Monday Jul 08, 2024 by Dow Jones
8:35AM ET on Monday Jul 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Outlook Therapeutics Inc | 195.2M | -0.7x | --- |
Biomea Fusion Inc | 196.3M | -1.6x | --- |
Candel Therapeutics Inc | 193.7M | -5.2x | --- |
Fractyl Health Inc | 193.5M | -2.4x | --- |
Ventyx Biosciences Inc | 204.4M | -0.9x | --- |
Acumen Pharmaceuticals Inc | 204.9M | -3.3x | --- |
Company Information
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Contact Information
- Headquarters
- 111 S. Wood Avenue, Unit #100ISELIN, NJ, United States 08830
- Phone
- 609-619-3990
- Fax
- ---
Executives
- Director
- Ralph Thurman
- President, Chief Executive Officer, Director
- C. Russell Trenary
- Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
- Lawrence Kenyon
- Senior Vice President - Head of Europe
- Jedd Comiskey
- Senior Vice President - Licensing and M&A
- Joel Prieve
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $195.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-11.48 |
Book Value | $-1.11 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
